Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes Spiel AO; Gilbert JC; Jilma BCirculation 2008[Mar]; 117 (11): 1449-59von Willebrand factor (VWF) plays a pivotal role in platelet adhesion and aggregation at sites of high shear rates (eg, in coronary arteries that have stenotic or ruptured atherosclerotic plaque lesions). Numerous studies have investigated the relationship between VWF plasma levels and thromboembolic cardiovascular events. In contrast to the rather weak association in the general population, in patients with preexisting vascular disease, VWF is significantly predictive for adverse cardiac events, including death. Likewise, VWF typically rises during the course of acute coronary syndrome, and the extent of this VWF release is an independent predictor of adverse clinical outcome in these patients. Various lines of evidence indicate that VWF is not only a marker but also actually an important effector in the pathogenesis of myocardial infarction. This central role of VWF in thrombogenesis has made it a promising target for research into new antiplatelet therapies that specifically inhibit VWF. This review focuses on the role of VWF in acute coronary syndrome and further outlines the relevance of therapeutic interventions targeting VWF for acute coronary syndrome patients.|Acute Disease[MESH]|Angioplasty, Balloon, Coronary[MESH]|Biomarkers[MESH]|Cardiovascular Diseases/*blood/epidemiology[MESH]|Coronary Artery Disease/blood/complications[MESH]|Coronary Thrombosis/blood/etiology[MESH]|Endothelium, Vascular/injuries/metabolism[MESH]|Hemorheology[MESH]|Humans[MESH]|Myocardial Infarction/blood/drug therapy/therapy[MESH]|Platelet Activation/physiology[MESH]|Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors[MESH]|Platelet Membrane Glycoproteins/antagonists & inhibitors[MESH]|Receptors, Cell Surface/antagonists & inhibitors[MESH]|Risk Factors[MESH]|Rupture, Spontaneous[MESH]|Syndrome[MESH]|Thrombolytic Therapy[MESH]|Thrombosis/*blood[MESH]|von Willebrand Factor/analysis/*physiology[MESH] |
